全文获取类型
收费全文 | 1540篇 |
免费 | 106篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 58篇 |
妇产科学 | 9篇 |
基础医学 | 187篇 |
口腔科学 | 11篇 |
临床医学 | 164篇 |
内科学 | 347篇 |
皮肤病学 | 18篇 |
神经病学 | 106篇 |
特种医学 | 203篇 |
外科学 | 115篇 |
综合类 | 27篇 |
一般理论 | 1篇 |
预防医学 | 107篇 |
眼科学 | 18篇 |
药学 | 128篇 |
肿瘤学 | 166篇 |
出版年
2023年 | 5篇 |
2022年 | 12篇 |
2021年 | 26篇 |
2020年 | 7篇 |
2019年 | 21篇 |
2018年 | 26篇 |
2017年 | 26篇 |
2016年 | 20篇 |
2015年 | 24篇 |
2014年 | 33篇 |
2013年 | 40篇 |
2012年 | 49篇 |
2011年 | 57篇 |
2010年 | 43篇 |
2009年 | 25篇 |
2008年 | 60篇 |
2007年 | 74篇 |
2006年 | 58篇 |
2005年 | 64篇 |
2004年 | 51篇 |
2003年 | 40篇 |
2002年 | 46篇 |
2001年 | 50篇 |
2000年 | 30篇 |
1999年 | 24篇 |
1998年 | 41篇 |
1997年 | 60篇 |
1996年 | 37篇 |
1995年 | 39篇 |
1994年 | 27篇 |
1993年 | 22篇 |
1992年 | 29篇 |
1991年 | 38篇 |
1990年 | 33篇 |
1989年 | 41篇 |
1988年 | 40篇 |
1987年 | 35篇 |
1986年 | 39篇 |
1985年 | 34篇 |
1984年 | 30篇 |
1983年 | 18篇 |
1982年 | 34篇 |
1981年 | 14篇 |
1980年 | 27篇 |
1979年 | 18篇 |
1978年 | 24篇 |
1977年 | 20篇 |
1976年 | 21篇 |
1975年 | 8篇 |
1967年 | 4篇 |
排序方式: 共有1669条查询结果,搜索用时 46 毫秒
1.
2.
3.
Golli M; Van Nhieu JT; Mathieu D; Zafrani ES; Cherqui D; Dhumeaux D; Vasile N; Rahmouni A 《Radiology》1994,190(3):741
4.
B G Redman L Flaherty S Martino M Kraut C Wisniewski M Valdivieso J J Bander 《American journal of clinical oncology》1992,15(4):340-343
Administration of high-dose IL-2 results in hemodynamic changes that are similar to those seen in septic shock. These include a decrease in systemic vascular resistance (SVR) with a resultant drop in mean arterial pressure (MAP). Hypocalcemia is seen in septic shock and with IL-2 administration. Calcium replacement in septic shock has been reported to result in hemodynamic improvement; we therefore administered calcium to patients receiving high dose IL-2 to correct ionized hypocalcemia. Five consecutive patients underwent invasive hemodynamic monitoring before and during IL-2 administration. Calcium chloride was administered to correct ionized hypocalcemia, and hemodynamic parameters were monitored before and after calcium administration. Ionized hypocalcemia was associated with an elevation in parathyroid hormone levels. There was no toxicity related to the administration of calcium. An improvement in the MAP and SVR was seen early and late (after a dose of IL-2 was held) in the IL-2 treatment cycle; there were minimal effects at other points. Because of the potential hemodynamic benefit of calcium replacement, we recommend that ionized hypocalcemia be corrected in patients receiving high-dose IL-2. 相似文献
5.
6.
7.
8.
9.
MGC Hendriks P Dogterom JT Ebels B Oosterhuis LR Geertsema T Hulot G Bianchetti and JHG Jonkman 《Fundamental & clinical pharmacology》1998,12(5):559-565
Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)1, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (cmin), the maximum plasma concentration (cmax), the time to reach that concentration (tmax), the time interval during which the plasma concentration exceeds 50% of cmax (t50), the area under the plasma concentration-time curve (AUC72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC72–96 (AUCNDM and AUCDAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated. 相似文献
10.
Intestinal obstruction proximal to a transition zone without an interposed physical barrier usually indicates Hirschsprung disease. The authors report one case of focal small bowel muscular thinning just distal to a transition zone that produced clinical and radiographic findings that simulated long-segment Hirschsprung disease in a 2-day-old infant. 相似文献